2010
DOI: 10.1590/s0074-02762010000500017
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Protection against Fasciola hepatica in goats immunized with a synthetic recombinant antigen from Schistosoma mansoni fatty acid-binding protein 14 (rSm14) was investigated by assessing worm burdens, serum levels of hepatic enzymes, faecal egg count and hepatic damage, which was evaluated using gross and microscopic morphometric observation. The nature of the local immune response was assessed by examining the distribution of CD2+, CD4+, CD8+ and γ´+ T lymphocytes along with IgG+, IL-4+ and IFN-γ+ cells in the… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
16
0

Year Published

2012
2012
2021
2021

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 25 publications
(18 citation statements)
references
References 36 publications
2
16
0
Order By: Relevance
“…Further analysis confirmed these initial findings and also demonstrated that vaccination with rSm14 can protect the natural host of F. hepatica , the sheep, against experimental parasite challenge resulting in complete abolition of liver pathology ( 34 ). In independent experiments undertaken in Spain, protection against fasciola infection was later also achieved in goats immunized with rSm14, where again significantly reduced liver damage was recorded ( 35 ). Several groups around the world have been undertaking studies to evaluate the potential of FABPs homologous to Sm14 derived from various organisms as vaccines against a number of different helminth diseases.…”
Section: Rsm14 As a Multi-specific Anti-helminth Vaccinementioning
confidence: 99%
“…Further analysis confirmed these initial findings and also demonstrated that vaccination with rSm14 can protect the natural host of F. hepatica , the sheep, against experimental parasite challenge resulting in complete abolition of liver pathology ( 34 ). In independent experiments undertaken in Spain, protection against fasciola infection was later also achieved in goats immunized with rSm14, where again significantly reduced liver damage was recorded ( 35 ). Several groups around the world have been undertaking studies to evaluate the potential of FABPs homologous to Sm14 derived from various organisms as vaccines against a number of different helminth diseases.…”
Section: Rsm14 As a Multi-specific Anti-helminth Vaccinementioning
confidence: 99%
“…However, numerous trials have shown no significant or discrete protection (Toet et al., ; Yap & Smooker, ). Some trials using recombinant antigens have shown very high protection, for example, a trial using recombinant Schistosoma mansoni 14 antigen (rSm14) in RIBI adjuvant, induced 98.5% protection in (Almeida et al., ), although the groups were small ( n = 4), and protection was not confirmed in subsequent trials in goats (Mendes et al., ). A second study used rLAP from F. hepatica given in different adjuvants in sheep, and led to a reduction in fluke burden of 74% and 86% with adjuvac 50 and alum adjuvant, respectively (Maggioli et al., ).…”
Section: Vaccine Developmentmentioning
confidence: 99%
“…Previous studies have shown that vaccines containing FABPs induce partial immune protection in experimentally infected mice and sheep (25, 26). Moreover, F. hepatica FABPs also appear to be important molecules for inducing cross-immunity against Schistosoma species (27). Although numerous published papers have explored the vaccine potential of F. hepatica FABPs, no studies have investigated whether FABPs have anti-inflammatory effects or whether they may interact with cells of the host immune system.…”
Section: Introductionmentioning
confidence: 99%